

## CONTENTS

|   |             |          |
|---|-------------|----------|
| <i>List of figures</i>  | <i>page</i> | xiv      |
| <i>List of tables</i>   |             | xv       |
| <i>Foreword by Chief Justice Sundaresh Menon</i>                            |             | xvii     |
| <i>Preface</i>  | xxi         |          |
| <i>Acknowledgements</i>   | xxiv        |          |
| <b>1 Economic integration, Asia and medicines</b>                           |             | <b>1</b> |
| 1.1 Introduction – globalization and Asia                                   |             | 1        |
| 1.2 Aging Asia: healthcare needs  | 4           |          |
| 1.3 Diseases in Asia and the Pacific region                                 |             | 6        |
| 1.4 Poverty in Asia   | 8           |          |
| 1.5 The growth of National Health Expenditure                               |             | 9        |
| 1.6 Medicines, R&D and Asia – an overview                                   |             | 16       |
| 1.7 Economic integration activities in Asia and health matters: an overview | 22          |          |
| 1.8 TRIPS-plus requirements and Asia – an introduction                      | 24          |          |
| 1.9 New legal risks – potential of investor-state claims                    | 26          |          |
| 1.10 Syncopation between the law, science and social policy                 | 26          |          |
| 1.11 The role of international organizations                                |             | 27       |
| 1.12 The global and regional context  |             | 29       |
| 1.13 Economic reform and IPRs in Asia                                       |             | 41       |
| 1.14 Conclusion   | 44          |          |

|          |   |            |
|----------|---|------------|
| <b>2</b> | <b>Access to medicines, innovation and the debate at the multilateral level</b>   | <b>46</b>  |
| 2.1      | Globalization, trade and public health dimensions: The context                    | 46         |
| 2.2      | Government reviews on the pharmaceutical sector and patents                       | 56         |
| 2.3      | International patent commitments: from Paris to Uruguay and beyond                | 57         |
| 2.4      | The promise of TRIPS: flexibilities for members                                   | 58         |
| 2.5      | Regulatory tensions   | 62         |
| 2.6      | The place of patents in the debate  | 66         |
| 2.7      | A very contentious debate   | 81         |
| 2.8      | Other relevant elements of the debate   | 83         |
| 2.9      | Conclusion  | 99         |
| <b>3</b> | <b>Trade, investment and medicines: the existing legal and policy construct</b>   | <b>101</b> |
| 3.1      | The existing legal and policy construct   | 101        |
| 3.2      | ASEAN – the need for greater clarity in the collective legal and policy construct | 103        |
| 3.3      | Key elements  | 103        |
| 3.4      | Exhaustion of rights and parallel imports   | 159        |
| 3.5      | Conclusion  | 162        |
| <b>4</b> | <b>Treaties in Asia: embedded risks and lessons from disputes elsewhere</b>       | <b>164</b> |
| 4.1      | Legal obligations in TRIPS  | 164        |
| 4.2      | Examples of TRIPS disputes in the WTO system                                      | 165        |
| 4.3      | TRIPS-like and TRIPS-plus commitments in Asia FTAs                                | 167        |

|   |            |
|---|------------|
| 4.4 FTAs and legal risks arising from negotiated language                                       | 168        |
| 4.5 Non-FTA mechanisms with a bearing on national laws  | 172        |
| 4.6 Types of TRIPS-plus FTA provisions  | 172        |
| 4.7 The treaty-based ISDS system – legal risks and concerns                                     | 201        |
| 4.8 “Counterweight” provisions relevant to the regulation of the pharmaceutical industry        | 214        |
| 4.9 Conclusion  | 215        |
| <b>5 The importance of exceptions and flexibilities</b>   | <b>219</b> |
| 5.1 Introduction  | 219        |
| 5.2 Exception provisions – general considerations   | 221        |
| 5.3 Applicability of GATT 1994 Article XX to WTO Accession Protocol commitments: lessons learnt | 224        |
| 5.4 Safe harbours: Asian treaties’ general exceptions   | 225        |
| 5.5 TRIPS principles and objectives in FTAs   | 227        |
| 5.6 TRIPS exceptions and flexibilities  | 228        |
| 5.7 Using a non-violation provision to safeguard the use of exceptions and limitations          | 266        |
| 5.8 Investment treaty general exceptions and expropriation exceptions relevant to health        | 268        |
| 5.9 Security exceptions   | 273        |
| 5.10 Interpretational treaty signals  | 275        |
| 5.11 Negotiating space  | 277        |
| 5.12 Conclusion   | 281        |
| <b>6 Innovation and competition</b>   | <b>283</b> |
| 6.1 Innovation, competition: seeking a balance  | 283        |

|     |  |            |
|-----|--|------------|
| 6.2 | Patents and competition law – necessary bedfellows   | 286        |
| 6.3 | Emerging case law on competition law and pharmaceutical patentees’ practices   | 289        |
| 6.4 | The European Union: towards increased competition enforcement in pharmaceuticals sector                                | 294        |
| 6.5 | Asia’s first pay-for-delay case  | 297        |
| 6.6 | Developments in other jurisdictions  | 298        |
| 6.7 | Connecting refusals to licence patents and the essential facilities doctrine: the next logical step?                   | 302        |
| 6.8 | Competition law and the pharmaceutical sector in Asia – an evolving regional landscape                                 | 306        |
| 6.9 | Conclusion   | 332        |
| 7   | <b>Setting new directions: the need for innovative legal and policy solutions</b>                                      | <b>334</b> |
| 7.1 | The need for new paradigms and strategies  | 334        |
| 7.2 | A brief inventory of major initiatives   | 337        |
| 7.3 | The evolving role of the state as a provider of incentives   | 342        |
| 7.4 | The evolving paradigm in R&D: public-private partnerships to promote public health and innovation                      | 344        |
| 7.5 | Exploring new funding models   | 348        |
| 7.6 | The evolving role of business  | 352        |
| 7.7 | Rethinking clinical data protection  | 353        |
| 7.8 | Treaty-based approaches  | 366        |
| 7.9 | The use of differential or tiered pricing: affordable prices and facilitative aspects in trade and investment treaties | 377        |

|      |   |     |
|------|---|-----|
| 7.10 | Dispute resolution provisions for public health                                   | 387 |
| 7.11 | Conclusion  | 388 |
| 8    | What next?  | 389 |
| 8.1  | Advancing access: important questions and trends for Asia to consider             | 389 |
| 8.2  | Clarifying critical matters in the multilateral trade system                      | 389 |
| 8.3  | New incentives – new ways of rewarding conduct that contributes to greater access | 404 |
| 8.4  | Timely evaluations and coherent policy-making in growing areas                    | 405 |
| 8.5  | Can industry do more?   | 411 |
| 8.6  | Can governments do more?  | 418 |
| 8.7  | Regional integration and pharmaceutical initiatives                               | 422 |
| 8.8  | Watch this space: BRICS and health  | 430 |
| 8.9  | Encouraging new alliances and collaborations                                      | 432 |
| 8.10 | Preparing for the debate ahead: legal education and capacity-building             | 435 |
| 8.11 | Conclusion  | 436 |
|      | <i>Index</i>  | 439 |